Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(15):1183-1184; doi:10.1093/jnci/djh235
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Saad, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Saad, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

Fred Saad

Correspondence to: Fred Saad, MD, FRCS, Division of Urologic Oncology, University of Montreal Hospital Center, 1560 Sherbrooke East, Montreal, PQ, Canada H2L 4M1 (e-mail: fred.saad.chum@ssss.gouv.qc.ca)

The first 10% of the full text of this article appears below.

Drs. Winquist and Berry stated that, because in our trial "the rate of skeletal-related events (SREs) was 44.2%" (1), there is not adequate rationale for routine use of bisphosphonates in patients with bone metastases from advanced prostate cancer. However, we believe that the evidence supports the routine use of zoledronic acid in these patients. After 24 months of follow-up, 49% of patients in the placebo arm had experienced at least one . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
K. J. Pienta and D. C. Smith
Advances in Prostate Cancer Chemotherapy: A New Era Begins
CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318.
[Abstract] [Full Text] [PDF]